Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? [Yahoo! Finance]
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success [Yahoo! Finance]
J&J and Protagonist's icotrokinra scores in Phase IIb UC study [Yahoo! Finance]
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at Truist Financial Co. from $60.00 to $76.00. They now have a "buy" rating on the stock.